Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
There are some remissions, but peripheral neuropathy casts a long shadow.
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
With telaglenastat facing a risky trial readout Calithera picks up two bargain-basement oncology projects to pivot to.